Search any bill in Congress.

The bill aims to amend the Public Health Service Act to temporarily limit the use of rebates within the 340B Drug Pricing Program. The 340B Program allows certain hospitals and healthcare providers to purchase outpatient drugs at reduced prices, helping them stretch federal resources to serve more patients, particularly those who are low-income or uninsured. Rebates in this context typically refer to discounts or refunds that drug manufacturers provide to these covered entities. By temporarily limiting the use of these rebates, the bill seeks to modify how savings are calculated or distributed under the program. This could affect the financial operations of hospitals and clinics participating in 340B, potentially influencing their ability to provide discounted medications. The temporary nature suggests this is a short-term measure, possibly to address concerns about program costs or abuses. The practical impact would depend on the specifics of the rebate limitations, which could alter drug pricing dynamics and funding for safety-net providers.